Regulation & Compliance

With a $15 million funding boost, Nasus Pharma is accelerating its powder-based intranasal epinephrine, NS002, challenging the EpiPen's dominance.

Jasmine Hartin is vindicated as drug and assault charges are dismissed, raising questions about a 'weaponized' legal system in her ongoing public saga.

Irish firm InVera Medical wins CE Mark for a new varicose vein device, promising a less invasive, office-based treatment for a widespread condition.

Comparor launches its AI assistant, joining a tech race to simplify shopping and find the best price. But what does this mean for you and for retailers?

STADA and Bio-Thera's new golimumab biosimilar wins European approval, promising to slash healthcare costs and expand treatment access for millions.

Byreal's 2026 roadmap, revealed at Solana Accelerate, promises AI-driven liquidity and 24/7 real-world asset trading, aiming to woo institutions.

Magna beat Q4 expectations and raised its dividend, but a $591M tech impairment and looming Ford recall costs paint a complex picture for the auto giant.

The firm is enhancing its cross-border support to help clients navigate complex international tax, legal, and investment landscapes in a globalized world.

Global broker PU Prime gains a coveted CMA license, deepening its regulatory footprint and opening doors to the UAE's rapidly evolving financial landscape.

With a fresh $25M, Uptiq is tackling AI's biggest hurdle in finance: moving from demos to deployment with its compliance-first Qore platform.

A new high-tech facility in France aims to tackle the global mountain of textile waste, promising infinitely recyclable polyester and a greener future.

As Guardian Pharmacy Services prepares for a key investor conference, it showcases strong growth while its industry faces a looming crisis. Can its model work?

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

A federal agency's safety warning has sparked a high-stakes legal fight, pitting a small business against regulators in a battle over science and survival.

Vitalist reports soaring losses and a $6.4M debt surge, raising 'going concern' alarms. Can its new Reebok smartwatches and VitalOS™ platform save it?

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

Lay's emotional 'Last Harvest' was America's top Super Bowl ad, but a new report reveals a huge generational divide, with Gen Z crowning a different winner.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

A jury verdict against Olin Corporation in a contract dispute with Shintech will cost the chemical giant $185 million and raises industry-wide questions.

The Midwest bank saw record earnings and shareholder returns in 2025, but a rise in nonperforming loans adds a layer of complexity to its growth story.